- We are particularly encouraged by the durable benefit, with patients remaining on treatment for much longer than expected. More than 10 months median time to progression is significantly longer than previously achieved with second-line treatment with Lenvima monotherapy or other treatment options, says
Read the full article at biostock.se:
https://www.biostock.se/en/2024/06/medivir-presents-promising-results-in-difficult-to-treat-patient-population/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se
https://news.cision.com/medivir/r/biostock-medivir-presents-promising-results-in-difficult-to-treat-patient-population,c4007314
(c) 2024 Cision. All rights reserved., source